Phase 2 N=74 Preventive Approach to Congenital Heart Block With Hydroxychloroquine
Congenital Heart Block · Neonatal Lupus · Autoantibody-Associated Heart Block
Primary: Recurrence of Advanced Heart Block — 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=10 Pacemaker Therapy in Adults With Congenital Heart Defects
Congenital Disorder
Primary: Feasibility of Pacemaker Implant With Total Thoracoscopic Approach to Epicardial Pacing Lead — 100 percentage of particiapants
N/A N=151 Systemic Lupus Erythematous and Heart Conduction Disorders
Lupus Erythematosus, Systemic · Atrioventricular Block · Sudden Death
Primary: Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile — 89.22; 91.41; 145.68; 146.72 msec
N/A N=918 Biventricular Versus Right Ventricular Pacing in Heart Failure Patients With Atrioventricular Block (BLOCK HF)
Atrioventricular Block · Heart Diseases
Primary: Mortality, Heart Failure-related Urgent Care Visits, or Significant Increase in Left Ventricular End Systolic Volume Index (LVESVI) — 160; 191; 93; 136 participants…
N/A N=34 Assessing the Hemodynamic Benefits of Cardiac Resynchronization Therapy in Children Following Open-Heart Surgery
Congenital Heart Defects
Primary: Cardiac Index — 3.39; 3.42; 3.23 L/min/m2
Phase 4 N=810 CryoCath Freezor CryoAblation Catheter System (CRYOFACTS)
Tachycardia, Atrioventricular Nodal Reentry
Primary: Device or Procedure Related AV Block Persistent Through Discharge From Hospital. — 0; 0 participants
N/A N=1,833 Biopace Study: Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization
Atrioventricular Block · Ventricular Dysfunction
Primary: Total Mortality — 307; 305 Participants — p=0.3492
N/A N=60 Heart Function in HIV-Negative Children Exposed to HIV and HAART
HIV Infections
Primary: Left Ventricular Mass Index — 67; 60 g/m2 — p=0.27
N/A N=101 Prevention of Syncope by Cardiac Pacing in Patients With Bifascicular Block
Bifascicular Block · Syncope
Primary: Combined Endpoint Defined as First Occurrence Among the Following Events 1)Syncope Episode of Any Origin; 2)Presyncopal Episode With Documented Cardioinhibitory Origin…
Phase 2 N=19 Abdominal Nerve Blockade in Chronic Heart Failure.
Heart Failure
Primary: Exercise Capacity as Measured by Peak Oxygen Uptake (Peak VO2) — 9.1; 9.8 mL/kg/min — p=0.053
N/A N=2,569 Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease
Severe Respiratory Syncytial Virus Infection
Primary: Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Serious Infection, Serious Arrhythmia and/or Death — 303; 349 participants
N/A N=34 Pilot Study of B-Type Natrieutic Peptide (BNP) Levels in Patients With Congenital Heart Disease(BNP)
Congenital Heart Disease · Cardiovascular Disease
Primary: BNP Levels — 16.3; 42.4; 384.3 pg/ml
Phase 2 N=129 Adenosine to Assess Complete Conduction Block During Catheter Ablation of Paroxysmal Atrial Fibrillation
Atrial Fibrillation
Primary: Freedom From Any Atrial Arrhythmias — 24; 23 Participants — p=.83
N/A N=33 Noninvasive Measurement of CO Using Impedance Cardiography in Patients With CHD
Congenital Heart Disease
Primary: Mean Difference in Stroke Volume Between CMR and SMIC — 1.7 ml — p=0.47
Phase 1 N=14 Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single Ventricle Physiology
Hypoplastic Left Heart Syndrome · Single Ventricle · Heart Failure
Primary: Feasibility Evaluation and Major Cardiac Adverse Events Related to Transcoronary Infusion of Cardiac Progenitor Cells — 0; 0 participants
N/A N=186 BIOTRONIK Conduction System Pacing With the Solia Lead
Bradycardia · Atrioventricular Block · Left Bundle-Branch Block
Primary: Serious Adverse Device Effect (SADE)-Free Rate at 3 Months — 98 Percentage of participants without SADE — p=<0.0001
N/A N=165 Influence of Genetic Polymorphisms on Ventricular Structure and Function in Patients With Single Ventricle Anatomy
Congenital Heart Disease
Primary: To Evaluate the Incidence of the Pre-proendothelin SNP at Nucleotide 5665 — 10 participants
N/A N=240 PROTECT-PACE STUDY - The Protection of Left Ventricular Function During Right Ventricular Pacing
Left Ventricular Dysfunction
Primary: Change in Left Ventricular Ejection Fraction From Baseline to 2 Years (Intent to Treat Cohort). — -2.29; -3.43 percentage — p=0.4347
N/A N=20 ECG Belt to Assess Electrical Synchronization
Bradycardia · Heart Failure
Primary: • ECG Belt Analysis of Standard Deviation of Activation Times (SDAT) of LBBP Compared to Native Conduction — 38.6; 20.5 ms
N/A N=242 CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients
Non-left Bundle Branch Block · Ischemic or Non-ischemic Cardiomyopathy
Primary: Number of Patients With Improved Clinical Composite Score — 86; 45 Participants — p=0.001
Phase 2 N=17 Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis
Cardiac Sarcoidosis
Primary: Change in Inflammation Marker — -43; 7 mg/L
N/A N=26 Junctional AV Ablation in CRT-D: JAVA-CRT
Systolic Heart Failure · Atrial Fibrillation (Permanent)
Primary: Number of Patients With Reduction ≥ 15% in Left Ventricular End-systolic Volume (LVESV) — 5; 6 Participants — p=1.00
N/A N=66 Congenital Heart Adolescents: Program of Transition Evaluation Research
Congenital Heart Defects
Primary: Transition Readiness Assessment Questionnaire (TRAQ) Score — 2.77; 2.95; 3.80; 3.92 units on a scale
N/A N=41 His Bundle Pacing Versus Coronary Sinus Pacing for Cardiac Resynchronization Therapy
Congestive Heart Failure
Primary: Change in Left Ventricular Ejection Fraction (LVEF) — 26.3; 30.5; 31.9; 34.0 ejection fraction percentage — p=<0.001
N/A N=190 Attain Model 4196 Left Ventricular (LV) Lead
Heart Failure
Primary: Safety (Subjects Without a Model 4196 Lead Related Complication) — 168 participants
N/A N=63 Intra-procedural Transthoracic EChocardiogram to Facilitate Left Bundle Branch Area Pacing (LBBAP)
Heart Failure
Primary: A Positive Success Rate of LBBAP Utilization With Intraprocedural Transthoracic Echocardiogram — 19; 10 Participants
N/A N=10 Endothelin Blockade in Patients With Single Ventricle Physiology
Congenital Heart Disease
Primary: Pulmonary Blood Flow as Determined by MRI Velocity Encoding at 3-6 Months — 3.3; 4.4 L/min — p=0.03
N/A N=119 Early Identification of Myocardial Impairment in PBC
Primary Biliary Cholangitis · Cardiovascular Abnormalities
Primary: The Incidence of Cardiac Events — 0; 0; 0; 0 Participants — p=0.001
N/A N=80 Supraventricular Tachycardia Collection Study
Supraventricular Arrhythmias
Primary: Number of Electrocardiograms (ECGs) Collected — 77; 67; 53 ECG
N/A N=302 Clinical Evaluation of the Blazer® Open-Irrigated Catheter for Treatment of Type 1 Atrial Flutter
Atrial Flutter
Primary: Procedure-related Complication-free Rate — 92.7; 98.2 percentage of subjects